Biohit Oyj (HEL:BIOBV)

Market Cap	43.12M
Revenue (ttm)	14.28M
Net Income (ttm)	2.57M
Shares Out	15.18M
EPS (ttm)	0.17
PE Ratio	16.77
Forward PE	18.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,422
Average Volume	5,432
Open	2.800
Previous Close	2.840
Day's Range	2.700 - 2.820
52-Week Range	1.915 - 4.350
Beta	0.69
RSI	36.52
Earnings Date	Mar 19, 2025

About Biohit Oyj

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company’s diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist clinicians and general practitioner; Biohit Active B12, a test for measuring the levels of active vitamin B12; BIOHIT Total 25OH Vitamin D, a test for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 46
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: BIOBV

Financial Performance

In 2024, Biohit Oyj's revenue was 14.28 million, an increase of 9.23% compared to the previous year's 13.08 million. Earnings were 2.57 million, an increase of 38.74%.